Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.19 USD | +2.24% | -8.86% | +12.32% |
May. 09 | Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
Apr. 17 | DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 75.63 | 241.8 | 124.6 | 56.61 | 142.8 | 165.7 | - | - |
Enterprise Value (EV) 1 | 75.63 | 207 | 124.6 | 56.61 | 142.8 | 165.7 | 165.7 | 165.7 |
P/E ratio | -5.45 x | -13 x | -5.74 x | -3.04 x | -4.73 x | -4.6 x | -3.71 x | -4.56 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | -4.49 x | -17.6 x | - | - | -4.96 x | -4.25 x | -3.06 x | -3.03 x |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 12,007 | 18,739 | 26,439 | 26,443 | 37,954 | 37,958 | - | - |
Reference price 2 | 4.850 | 10.14 | 3.730 | 1.580 | 2.840 | 3.190 | 3.190 | 3.190 |
Announcement Date | 3/23/20 | 3/10/21 | 3/14/22 | 3/28/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA 1 | -16.83 | -13.7 | - | - | -28.81 | -39 | -54.05 | -54.6 |
EBIT 1 | -16.86 | -16.06 | -17.41 | -19.07 | -28.85 | -38.11 | -48.99 | -54.74 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -15.44 | -15.51 | -17.31 | -18.59 | -26.24 | -36.17 | -47.35 | -54.74 |
Net income 1 | -15.49 | -15.55 | -17.34 | -18.63 | -26.3 | -36.08 | -47.35 | -54.74 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -0.8900 | -0.7800 | -0.6500 | -0.5200 | -0.6000 | -0.6933 | -0.8600 | -0.7000 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/23/20 | 3/10/21 | 3/14/22 | 3/28/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | - | - | - | - | -7.429 | -6.373 | -7.098 | -7.924 | -7.867 | -9.305 | -10.67 | -11.36 | -11.5 |
EBIT 1 | -4.249 | -4.142 | -4.535 | -4.294 | -4.209 | -5.412 | -7.452 | -6.383 | -7.109 | -7.934 | -7.878 | -9.032 | -10.26 | -11.02 | -11.5 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -4.283 | -4.133 | -4.49 | -4.277 | -4.107 | -5.1 | -7.106 | -6.018 | -6.154 | -6.972 | -7.059 | -8.598 | -9.762 | -10.23 | -11.5 |
Net income 1 | -4.291 | -4.142 | -4.499 | -4.286 | -4.116 | -5.109 | -7.116 | -6.027 | -6.164 | -7.002 | -7.069 | -8.566 | -9.762 | -10.23 | -11.5 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1800 | -0.1100 | -0.1300 | -0.1300 | -0.1200 | -0.1400 | -0.2000 | -0.1600 | -0.1200 | -0.1400 | -0.1400 | -0.1633 | -0.1867 | -0.1967 | -0.2200 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/10/21 | 3/14/22 | 5/4/22 | 8/10/22 | 11/9/22 | 3/28/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/19/24 | 5/8/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | 34.8 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/23/20 | 3/10/21 | 3/14/22 | 3/28/23 | 3/19/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.32% | 118M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- DMAC Stock
- Financials DiaMedica Therapeutics Inc.